Target Name: MIR651
NCBI ID: G723779
Review Report on MIR651 Target / Biomarker Content of Review Report on MIR651 Target / Biomarker
MIR651
Other Name(s): mir-651 | microRNA 651 | hsa-miR-651-5p | hsa-mir-651 | MIRN651 | hsa-miR-651-3p | MicroRNA 651

MIR651: A Protein Regulator of Cell Growth and Development

MIR651, also known as mir-651, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the reasons why MIR651 is of interest as a drug target is its ability to interact with several different proteins, including TGF-β1, PDGF, and NF-kappa-B. These proteins are involved in several different signaling pathways that are important for cell growth, differentiation, and survival, and MIR651 has been shown to regulate their activity.

One of the ways that MIR651 is involved in these signaling pathways is through its role in the TGF-β1 signaling pathway. TGF-β1 is a cytokine that plays a central role in cell growth and differentiation, and it is involved in the development of many different diseases, including cancer. MIR651 has been shown to regulate TGF-β1 activity by interacting with its receptor, SMAD6. This interaction allows MIR651 to regulate the activity of TGF-β1 and to play a role in the development of cancer.

Another way that MIR651 is involved in the TGF-β1 signaling pathway is through its role in the regulation of cell adhesion. Cell adhesion is the process by which cells stick together and form tissues, and it is an important part of the development and maintenance of tissues and organs. MIR651 has been shown to regulate cell adhesion by interacting with the protein PDGF. This interaction allows MIR651 to regulate the activity of PDGF and to play a role in the development of cancer.

MIR651 is also involved in the regulation of the NF-kappa-B signaling pathway, which is a signaling pathway that is important for inflammation and immune responses. NF-kappa-B signaling is involved in the regulation of a wide range of cellular processes, including the production of inflammatory cytokines and the regulation of cell death. MIR651 has been shown to regulate NF-kappa-B signaling by interacting with its receptor, NF-kappa-B2. This interaction allows MIR651 to regulate the activity of NF-kappa-B2 and to play a role in the development of autoimmune diseases.

In addition to its role in the TGF-β1 and NF-kappa-B signaling pathways, MIR651 is also involved in the regulation of cell growth and differentiation. It has been shown to play a role in the regulation of cell proliferation and to control the production of cellular organelles, such as mitochondria and endoplasmic reticulum.

MIR651 is also of interest as a drug target because of its role in the development of neurodegenerative diseases. Neurodegenerative diseases are a group of conditions that are characterized by the progressive loss of brain cells and the development of progressive neurological symptoms. MIR651 has been shown to play a role in the development of neurodegenerative diseases by regulating the activity of several different proteins, including TGF-β1, PDGF, and NF-kappa-B.

One of the ways that MIR651 is involved in the development of neurodegenerative diseases is through its role in the regulation of axon growth and differentiation. Axon growth and differentiation are the processes by which new neurons develop and mature, and they are an important part of the development and maintenance of neural circuits. MIR651 has been shown to regulate axon growth and differentiation by interacting with the protein PDGF. This interaction allows MIR651 to regulate the activity of PDGF and to play

Protein Name: MicroRNA 651

The "MIR651 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR651 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR6510 | MIR6511A1 | MIR6511A2 | MIR6511A3 | MIR6511A4 | MIR6511B1 | MIR6511B2 | MIR6512 | MIR6513 | MIR6514 | MIR6515 | MIR6516 | MIR652 | MIR653 | MIR654 | MIR655 | MIR656 | MIR657 | MIR658 | MIR659 | MIR660 | MIR661 | MIR662 | MIR663A | MIR663AHG | MIR663B | MIR664A | MIR664B | MIR665 | MIR668 | MIR670 | MIR671 | MIR6715A | MIR6715B | MIR6716 | MIR6717 | MIR6718 | MIR6719 | MIR6720 | MIR6721 | MIR6722 | MIR6724-1 | MIR6726 | MIR6727 | MIR6728 | MIR6729 | MIR6730 | MIR6731 | MIR6732 | MIR6733 | MIR6734 | MIR6735 | MIR6736 | MIR6737 | MIR6738 | MIR6739 | MIR6740 | MIR6741 | MIR6742 | MIR6743 | MIR6744 | MIR6746 | MIR6747 | MIR6748 | MIR6749 | MIR675 | MIR6750 | MIR6751 | MIR6752 | MIR6753 | MIR6754 | MIR6755 | MIR6756 | MIR6757 | MIR6758 | MIR6759 | MIR676 | MIR6760 | MIR6761 | MIR6762 | MIR6763 | MIR6764 | MIR6765 | MIR6766 | MIR6767 | MIR6768 | MIR6769A | MIR6769B | MIR6770-1 | MIR6770-2 | MIR6770-3 | MIR6771 | MIR6772 | MIR6773 | MIR6774 | MIR6775 | MIR6776 | MIR6777 | MIR6778 | MIR6779